Adding Pembrolizumab to Docetaxel Does Not Significantly Improve Outcomes in Patients with Previously Treated mCRPC By Ogkologos - April 9, 2025 786 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-921 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Extra or Missing Chromosomes May Help Cancer Cells Survive Treatment September 24, 2021 At 3-Year Follow-Up Nivolumab Plus Chemotherapy Continued to Demonstrate OS Improvement... February 27, 2024 Adjuvant Capecitabine-Containing Regimen Improves Modestly Overall Survival in Patients with Early... January 18, 2022 Should People Over Age 75 Be Screened for Colorectal Cancer? June 15, 2021 Load more HOT NEWS Mom with Breast Cancer Who Had A Year to Live Goes... GreaterGood’s Mask Donations Are Helping LA Family Housing Keep Homeless People... After Struggling With Chronic Illnesses Most of Her Life, This Author... The Benefits of Yoga During Cancer and How to Get Started
